Impact of neoadjuvant and adjuvant chemotherapy on invasive lobular carcinoma: A propensity score-matched analysis of SEER data.
Rurina WatanukiTetsu HayashidaTakamichi YokoeYuko KawaiMasayuki KikuchiAyako NakashojiAiko NagayamaTomoko SekiMaiko TakahashiYuko KitagawaPublished in: The breast journal (2020)
Invasive lobular carcinoma (ILC) has a different treatment response from invasive ductal carcinoma (IDC). We assessed whether perioperative chemotherapy was associated with improved prognosis in patients with ILC. Retrospective data of women who underwent surgery for ILC were extracted from the SEER database. Subjects were divided into non-chemotherapy and chemotherapy groups. Overall, 10 537 patients were included, and 2107 patients were stratified into each group after propensity score matching. Perioperative chemotherapy significantly improved 10-year survival rates for ILC, particularly in patients with large tumor size and lymph node metastases. Perioperative chemotherapy is effective for ILC patients with proper selection.
Keyphrases
- locally advanced
- lymph node
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- patients undergoing
- cardiac surgery
- rectal cancer
- peritoneal dialysis
- prognostic factors
- minimally invasive
- electronic health record
- big data
- nk cells
- adipose tissue
- metabolic syndrome
- early stage
- machine learning
- acute kidney injury
- deep learning
- pregnancy outcomes